Key Financials Snapshot

TTM · Standalone · ₹ in Cr
Market Cap
₹1680 Cr.
Stock P/E
42.7
P/B
3.3
Current Price
₹681.4
Book Value
₹ 209.5
Face Value
5
52W High
₹881
52W Low
₹ 343
Dividend Yield
0.37%

Paushak Overview

Business

Paushak Ltd. is an Indian chemical company primarily engaged in the manufacturing of specialty chemicals. While specific product details require access to their latest reports, companies in this sector typically focus on niche and complex chemistries, often serving as critical intermediates or performance additives for various industries. Their core business model involves large-scale manufacturing and supply of these specialized chemical products, predominantly on a business-to-business (B2B) basis, to sectors such as agrochemicals, pharmaceuticals, polymers, or other industrial applications. The company generates revenue by selling these manufactured specialty chemical products to its industrial clients.

Revenue Mix

Without access to specific financial reports, detailed segment breakdown is not publicly available. However, based on its "Chemicals" sector classification, Paushak Ltd. likely operates primarily within the specialty chemicals domain. This often involves distinct product lines that cater to different end-user industries (e.g., fluorochemicals, custom synthesis for pharmaceuticals, agrochemical intermediates, or performance chemicals). The revenue mix would be driven by the sales volume and pricing of these specialized products across its customer base.

Industry

The Indian chemicals industry is diverse, encompassing both commodity and specialty chemicals. Paushak Ltd. operates in the specialty chemicals segment, which is generally characterized by higher value addition, complex manufacturing processes, and often higher barriers to entry compared to commodity chemicals. The industry is competitive, with both domestic players and global companies having a presence. Paushak Ltd. likely positions itself as a reliable supplier with expertise in specific, complex chemistries, potentially focusing on niche applications or proprietary manufacturing processes. Its positioning would be against other specialty chemical manufacturers, both domestic and international, that cater to similar end-user industries.

MOAT

For a specialty chemical company like Paushak Ltd., competitive advantages often stem from:

Process Expertise: Developing and scaling up complex chemical reactions efficiently and safely.

R&D Capabilities: Ability to innovate, develop new products, or improve existing processes, leading to cost efficiencies or unique product offerings.

Customer Relationships & Switching Costs: For critical inputs, customers often face significant costs (re-qualification, testing) in switching suppliers, fostering long-term relationships.

Regulatory Compliance: Expertise in meeting stringent environmental, health, and safety standards, particularly for regulated industries like pharma and agrochemicals.

Growth Drivers

Key factors that could drive Paushak Ltd.'s growth over the next 3-5 years include:

"China Plus One" Strategy: Global companies diversifying supply chains away from China, leading to increased outsourcing and manufacturing opportunities for Indian chemical players.

Demand from End-User Industries: Sustained or growing demand from key sectors like agrochemicals (food security), pharmaceuticals (healthcare), and other industrial applications.

Capacity Expansion: Investment in new manufacturing capacities or debottlenecking existing ones to meet growing demand and expand market reach.

New Product Development: Successful R&D leading to the introduction of new, high-value specialty chemicals, opening up new market segments.

Import Substitution: Growing domestic demand allowing Indian manufacturers to substitute imports with locally produced chemicals.

Risks

Raw Material Price Volatility: Fluctuations in the prices of key feedstocks, many of which are crude oil derivatives or globally traded, can impact profitability.

Environmental & Regulatory Risks: Stringent environmental regulations and compliance costs, potential for plant shutdowns due to non-compliance, or changes in safety standards.

Intense Competition: Competition from domestic and international players can lead to pricing pressure and margin erosion.

Global Economic Slowdown: A downturn in the global economy can reduce demand from end-user industries.

Technological Obsolescence: Failure to keep pace with new technologies or greener chemistry processes.

Capital Intensity: The chemical manufacturing business is capital-intensive, requiring continuous investment in plant and machinery.

Management & Ownership

Paushak Ltd. is part of the Alembic Group, a well-established industrial conglomerate in India, indicating a strong promoter background. Typically, such companies have a promoter-driven management structure, often with professional executives overseeing day-to-day operations. The quality of management would hinge on their technical expertise in chemistry, strategic vision for growth, operational efficiency, and commitment to corporate governance. The ownership structure generally involves a significant stake held by the promoter group, with the remaining shares held by institutional investors, high-net-worth individuals, and the public.

Outlook

Paushak Ltd. operates in the specialty chemicals sector, an area with significant growth potential, particularly given the "China Plus One" global supply chain diversification trend and robust demand from key end-user industries like pharma and agrochemicals. The company's established presence within the Alembic Group provides a foundation of experience and resources. However, the business is capital-intensive, susceptible to raw material price volatility, and subject to evolving environmental regulations. Its future performance will largely depend on its ability to innovate new products, expand capacity efficiently, manage operational costs effectively, and navigate the competitive landscape while adhering to stringent compliance standards.

Paushak Share Price

Live · BSE / NSE · Inception: 1972
₹ | |
Volume
Price

Key Financials — Profit & Loss

₹ in Cr · Standalone · annual

Paushak Quarterly Results

#(Fig in Cr.) Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026 Jun 2026 Sep 2026
Net Sales 52 57 49 52 56 59 49 55 84 89
Other Income 4 4 6 0 2 1 1 8 3 2
Total Income 56 61 56 52 58 60 50 63 87 91
Total Expenditure 40 40 35 36 38 44 37 38 58 63
Operating Profit 16 21 21 16 20 16 12 25 29 28
Interest 0 0 0 0 0 0 0 1 1 1
Depreciation 4 4 4 4 4 4 5 8 8 8
Exceptional Income / Expenses 0 0 0 0 0 0 0 0 0 0
Profit Before Tax 12 17 17 12 16 11 7 16 19 19
Provision for Tax 2 3 2 3 4 3 1 4 4 5
Profit After Tax 10 14 15 10 12 9 6 13 15 14
Adjustments 0 0 0 0 0 0 0 0 0 0
Profit After Adjustments 10 14 15 10 12 9 6 13 15 14
Adjusted Earnings Per Share 4.2 5.8 6.2 3.9 4.9 3.5 2.5 5.1 6.1 5.5

Paushak Profit & Loss

#(Fig in Cr.) Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026 TTM
Net Sales 78 67 103 140 138 141 150 212 206 211 219 277
Other Income 3 5 3 3 5 6 5 9 20 14 12 14
Total Income 81 72 106 142 143 147 155 221 227 225 231 291
Total Expenditure 61 55 74 99 95 91 96 137 142 151 158 196
Operating Profit 19 17 32 43 47 57 59 84 85 74 73 94
Interest 0 0 0 0 0 0 0 0 0 0 1 3
Depreciation 3 3 3 4 4 5 9 13 14 15 21 29
Exceptional Income / Expenses 0 0 0 10 2 0 0 2 0 0 0 0
Profit Before Tax 17 14 29 49 45 52 50 72 71 59 50 61
Provision for Tax 4 3 7 10 10 14 13 18 17 9 11 14
Profit After Tax 12 11 21 39 35 37 38 54 54 49 39 48
Adjustments 0 0 0 0 0 0 0 0 0 0 0 0
Profit After Adjustments 12 11 21 39 35 37 38 54 54 49 39 48
Adjusted Earnings Per Share 4.8 4.3 8.4 15.8 14.2 15.1 15.3 21.9 22 20 15.9 19.2

Paushak Balance Sheet

#(Fig in Cr.) Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Shareholder's Funds 69 83 113 178 227 272 306 354 408 465 491
Minority's Interest 0 0 0 0 0 0 0 0 0 0 0
Borrowings 0 0 0 0 0 0 0 0 0 25 60
Other Non-Current Liabilities 2 4 9 22 26 30 34 39 47 37 43
Total Current Liabilities 11 7 22 15 16 27 27 22 26 44 65
Total Liabilities 82 94 144 214 270 329 367 415 481 572 660
Fixed Assets 20 35 37 38 41 51 147 149 152 141 377
Other Non-Current Assets 22 33 52 86 119 183 116 119 113 331 152
Total Current Assets 40 26 56 90 111 95 104 147 216 100 132
Total Assets 82 94 144 214 270 329 367 415 481 572 660

Paushak Cash Flow

#(Fig in Cr.) Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Opening Cash & Cash Equivalents 0 0 0 0 1 1 0 0 1 1 0
Cash Flow from Operating Activities 14 12 10 24 45 30 44 43 56 38 54
Cash Flow from Investing Activities -13 -11 -10 -0 -43 -29 -42 -38 -50 -57 -95
Cash Flow from Financing Activities -1 -2 -1 -23 -2 -2 -2 -4 -5 19 42
Net Cash Inflow / Outflow 0 -0 0 0 0 -1 -0 0 0 -1 0
Closing Cash & Cash Equivalent 0 0 0 1 1 0 0 1 1 0 0

Paushak Ratios

# Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Earnings Per Share (Rs) 4.84 4.26 8.37 15.8 14.16 15.13 15.25 21.9 22.04 20.03 15.95
CEPS(Rs) 5.93 5.52 9.69 17.37 15.94 17.14 18.91 27.34 27.66 26.1 24.62
DPS(Rs) 0.38 0.38 0.38 0.63 0.75 0.75 1.5 2.19 2.5 2.5 2.5
Book NAV/Share(Rs) 26.76 32.36 44.09 72.01 92.16 110.18 123.93 143.45 165.52 188.79 199.18
Core EBITDA Margin(%) 20.02 16.75 28.02 28.81 31.01 35.79 36.13 35.41 31.27 28.28 27.81
EBIT Margin(%) 19.91 19.6 27.65 35.21 32.96 36.62 33.54 34.16 34.49 27.93 23.57
Pre Tax Margin(%) 19.84 19.52 27.56 35.12 32.9 36.59 33.5 34.01 34.42 27.86 23.06
PAT Margin (%) 14.83 15.13 20.5 27.93 25.32 26.45 25.06 25.43 26.35 23.41 17.99
Cash Profit Margin (%) 18.18 19.57 23.73 30.7 28.49 29.97 31.07 31.75 33.06 30.5 27.77
ROA(%) 16.52 12.43 17.99 21.73 14.43 12.46 10.82 13.83 12.13 9.38 6.38
ROE(%) 19.7 14.43 21.89 26.8 17.25 14.95 13.03 16.38 14.27 11.3 8.22
ROCE(%) 26.29 18.63 29.44 33.73 22.45 20.7 17.44 22 18.68 13.11 9.74
Receivable days 92.19 93.68 95.95 93.12 77.61 76.49 88.33 79.25 91.28 91.01 91.32
Inventory Days 35.28 44.71 36.03 39.24 45.2 38.88 39.84 35.85 39.38 37.55 48.66
Payable days 96.33 94.23 108.65 95.87 98.56 132.67 181.06 134.15 127.37 149.54 202.64
PER(x) 15.28 16.97 19.22 16.04 15.27 69.06 85.18 35.48 28.91 28.19 21.67
Price/Book(x) 2.76 2.24 3.65 3.52 2.35 9.48 10.48 5.42 3.85 2.99 1.74
Dividend Yield(%) 0.51 0.52 0.23 0.25 0.35 0.07 0.12 0.28 0.39 0.44 0.72
EV/Net Sales(x) 2.44 2.78 3.99 4.47 3.86 18.26 21.34 9.02 7.61 6.72 4.25
EV/Core EBITDA(x) 9.75 10.66 12.76 14.57 11.22 45.5 53.96 22.73 18.48 19.17 12.73
Net Sales Growth(%) 12.91 -14.42 55.14 34.89 -1.15 2.24 6.45 41.47 -2.87 2.27 3.63
EBIT Growth(%) -7.52 -14.96 104.3 69.61 -7.48 13.62 -2.52 44.09 -1.92 -17.19 -12.54
PAT Growth(%) -4.43 -11.88 96.22 81.44 -10.38 6.83 0.84 43.59 0.64 -9.15 -20.36
EPS Growth(%) -4.43 -11.88 96.22 88.8 -10.38 6.83 0.84 43.59 0.64 -9.16 -20.36
Debt/Equity(x) 0.01 0 0.01 0 0 0 0 0 0 0.05 0.16
Current Ratio(x) 3.61 3.69 2.49 6.07 6.81 3.49 3.83 6.6 8.3 2.24 2.01
Quick Ratio(x) 2.78 2.48 1.95 4.86 5.81 2.98 3.13 5.58 7.46 1.75 1.45
Interest Cover(x) 276.45 239.88 295.24 360.16 592.57 1051.69 818.52 233.3 467.13 416.35 46.25
Total Debt/Mcap(x) 0 0 0 0 0 0 0 0 0 0.02 0.09

Growth Rates

Compounded annual
# 1 Year 3 Year 5 Year 10 Year
Sales CAGR +4% +1% +9% +11%
Operating Profit CAGR -1% -5% +5% +14%
PAT CAGR -20% -10% +1% +13%
Share Price CAGR -8% -4% -12% +24%
ROE Average +8% +11% +13% +16%
ROCE Average +10% +14% +16% +21%

Paushak Shareholding Pattern

Latest · Sep 2026
100% held
Promoters 67.28 %
FII 0.11 %
DII (MF + Insurance) 0.27 %
Public (retail) 32.34 %
# Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026 Jun 2026 Sep 2026
Promoter 66.9766.9766.9767.1367.1367.2867.2867.2867.2867.28
FII 0000.01000000.11
DII 0.290.340.40.530.530.710.670.250.070.27
Public 32.7432.6932.6432.3232.3332.0132.0532.4732.6532.34
Others 0000000000
Total 100100100100100100100100100100

Paushak Peer Comparison

Chemicals Edit Columns

Paushak Quarterly Price

10-year quarterly close · BSE
Show Value Show %

News & Updates

See more…

Paushak Pros & Cons

Pros

  • Company is almost debt free.

Cons

  • Company has a low return on equity of 11% over the last 3 years.
  • Debtor days have increased from 149.54 to 202.64days.
  • Stock is trading at 3.3 times its book value.
  • The company has delivered a poor profit growth of 1% over past five years.
Want to Start Investing in Top Unlisted Stocks?

Our experts help you choose the right stocks based on performance, risk, and growth potential.

whatsapp